天麻素对偏头痛患者外周血CGRP、NO和ET-1表达的影响

Influences of Gastrodin on CGRP,NO and ET1 Expression in Peripheral Blood of Migraine Patients

目的观察天麻素治疗偏头痛患者的临床疗效及血清中降钙素基因相关肽(CGRP)、一氧化氮(NO)及内皮素-1(ET-1)表达水平的影响。方法 80例偏头痛患者随机分为对照组和治疗组各40例,对照组在抗感染、降压、改善睡眠等常规治疗的基础上加用氟桂利嗪每晚10mg口服,治疗组则在常规治疗的基础上加用天麻素注射液600mg加入0.9%氯化钠溶液250mL静脉滴注。采集治疗前、治疗第10天及35例健康体检者的外周静脉血:1观察2组患者治疗前后VAS评分变化及其治疗有效率;2采用ELISA法检测并比较患者血清中的CGRP、NO及ET-1含量变化。结果 12组治疗后VAS评分均较治疗前降低,治疗组VAS评分低于对照组(P<0.05),治疗组总有效率高于对照组(P<0.05);2治疗前,对照组与治疗组间CGRP、NO及ET-1的表达无明显差异(P>0.05),与健康体检者比较,则明显增高(P<0.01);3治疗第10天,治疗组与对照组CGRP、NO及ET-1的表达较治疗前均下降(P<0.01),而治疗组较对照组下降明显(P<0.05)。结论天麻素能明显改善偏头痛患者临床症状,同时降低患者血清CGRP、NO及ET-1表达水平,这可能是天麻素缓解偏头痛症状的可能机制之一。

OBJECTIVE To observe the clinical effect of gastrodin in treating migraine and its influences on serum calcitonin gene related peptide（CGRP）, nitric oxide（NO） and endothelinl （ET1） expression. METHODS 80 cases with migraine were randomly divided into the treatment group and control group. Patients in the treatment group were given routine treatment plus 10 mg flunarizine every night. While those in the control group were given the routine treatment plus one-time injection of 600mg gastrodin per day. The peripheral venous bloods of the above patients together with 35 healthy people were collected be- fore and 10 days after treatment. OVAS grade changes of both groups and also the curative rates were observed and evaluated. ②ELISA method was adopted to compare the serum CGRP, NO and ET1 expression of patients. RESULTS ①After treat- ment, the VAS grades of both groups were reduced and the treatment group was lower than the control group（P〈0.05）. Also the curative rate of the treatment group was notably higher than that of the control group（P〈0.05） ; ②No evident differences of CGRP, NO and ET1 expression were noticed between the two groups before treatment（P〉0.05）, while these expression were much higher than those of the healthy group（P〈0.01） ; QCGRP, NO and ET1 expressions of both groups were detected to have been declined on the tenth day after treatment（P〈0.01）, and the treatment group was much lower than the ＇control group（P〈0.01）. CONCLUSION Gastrodin is efficient in improving clinical symptoms of patients with migraine and reducing the expre.ssion of CGRP,, NO and ET1 in the serum, which might be one of the mechanisms for its effective role in relieving migraine.